How generic drug sponsors can ask FDA to reconsider applications: new draft guidance explains
The FDA is clarifying instances where generic drug applicants can request that the agency reconsider an application, according to an updated
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
